TY - JOUR
AU1 - Neffen, Hugo
AU2 - Ivancevich, Juan
AB - Background Allergic rhinitis is a disease underestimated by patients, and underdiagnosed and thus undertreated by physicians since most of the patients present with symptoms of moderate-to-severe disease, overall diminished quality of life, impairing sleep quality and cognitive function, and a substantial impact on work productivity, school absenteeism, and costs. The relationship between treating physician and patients is crucial in all chronic diseases. Objectives Review the main changes and innovations of recent years in the ARIA guide- lines. Methods The most recent publications of the ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines were reviewed. Results ARIA 2016 strengthens the role of patients in the control and treatment of their symptoms by the use of technology, which improves physician-patient communication. The selection of pharmacotherapy for patients with allergic rhinitis (AR) depends on several factors, including age, prominent symptoms, symptom severity, control of AR, patient preferences, and cost. It confirms that inhaled corticosteroids are the most effective drugs for the management of seasonal or perennial allergic rhinitis, not surpassed by combination therapies with oral or topical antihistamines. On the other hand, no significant differences between the use of oral or topical antihistamines are evidenced. Allergen exposure and the resulting symptoms 
TI - ARIA 2017: a Review of Major Changes and Innovations
JF - Current Treatment Options in Allergy
DO - 10.1007/s40521-018-0166-4
DA - 2018-05-16
UR - https://www.deepdyve.com/lp/springer-journals/aria-2017-a-review-of-major-changes-and-innovations-wByZvfQOAf
SP - 266
EP - 273
VL - 5
IS - 2
DP - DeepDyve